Nasopharyngeal carcinoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
Created page with "{{Nasopharyngeal carcinoma}} {{CMG}} ==Overview== ==References== {{Reflist|2}} {{WikiDoc Help Menu}} {{WikiDoc Sources}} Category:Disease Category:Types of cancer..." |
m Bot: Removing from Primary care |
||
| (21 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Nasopharyngeal carcinoma}} | {{Nasopharyngeal carcinoma}} | ||
{{CMG}} | |||
{{CMG}} {{AE}}{{Homa}}{{Faizan}} | |||
==Overview== | ==Overview== | ||
Secondary prevention measures of nasopharyneal cancer include routine [[physical examination]] and [[imaging]] at scheduled intervals after treatment. [[Dental]] [[Screening (medicine)|screening]] and [[Screening (medicine)|screening]] for [[Thyroid cancer|thyroid cancers]] are recommended among [[patients]] who had received [[radiation therapy]] to the [[oral cavity]] and [[cervical]] region, respectively. | |||
==Secondary Prevention== | |||
===Follow up after treatment=== | |||
[[Patients]] treated for nasopharyngeal carcinoma should follow-up for [[secondary prevention]]. Follow-up measures are shown in the table below:<ref name="pmid23946171">{{cite journal| author=Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ et al.| title=Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 8 | pages= 917-23 | pmid=23946171 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946171 }} </ref><ref name="ChanGregoire2012">{{cite journal|last1=Chan|first1=A. T. C.|last2=Gregoire|first2=V.|last3=Lefebvre|first3=J.- L.|last4=Licitra|first4=L.|last5=Hui|first5=E. P.|last6=Leung|first6=S. F.|last7=Felip|first7=E.|title=Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up|journal=Annals of Oncology|volume=23|issue=suppl 7|year=2012|pages=vii83–vii85|issn=0923-7534|doi=10.1093/annonc/mds266}}</ref> | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center" | |||
| valign="top" | | |||
|+ | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Follow up}} | |||
! style="background: #4479BA; width: 400px;" | {{fontcolor|#FFF|Description}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
:Physical exam | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Every 1-3 months during the 1st year after treatment | |||
*Every 2-6 months during the 2nd year after treatment | |||
*Every 4-8 months between the 3rd and 5th years after treatment | |||
*Annually thereafter | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
:Nasoendoscopy | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Immediately following [[radiation therapy]] | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
:Scanning | |||
:*CT Scan | |||
:*MRI | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Scans are performed at routine intervals as follows: | |||
*Baseline scanning is performed at 3-6 months after treatment, further scans are scheduled based on finding of [[physical exam]] and [[symptoms]] experienced by the [[patient]] | |||
*Scanning for [[asymptomatic]] [[patients]] is not recommended | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
:Thyroid hormone testing | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*[[Thyroid stimulating hormone]] testing every 12 months if the [[neck]] was exposed to [[radiation]] | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
:Dental screening | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*Only recommended if [[oral cavity]] was exposed to [[radiation]] | |||
|- | |||
|} | |||
==References== | ==References== | ||
| Line 10: | Line 57: | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category: | [[Category:Up-To-Date]] | ||
[[Category:Medicine]] | |||
[[Category: | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Otolaryngology]] | |||
Latest revision as of 22:54, 29 July 2020
|
Nasopharyngeal carcinoma Microchapters |
|
Differentiating Nasopharyngeal carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Nasopharyngeal carcinoma secondary prevention On the Web |
|
American Roentgen Ray Society Images of Nasopharyngeal carcinoma secondary prevention |
|
Risk calculators and risk factors for Nasopharyngeal carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]Faizan Sheraz, M.D. [3]
Overview
Secondary prevention measures of nasopharyneal cancer include routine physical examination and imaging at scheduled intervals after treatment. Dental screening and screening for thyroid cancers are recommended among patients who had received radiation therapy to the oral cavity and cervical region, respectively.
Secondary Prevention
Follow up after treatment
Patients treated for nasopharyngeal carcinoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:[1][2]
| Follow up | Description |
|---|---|
|
|
|
|
|
Scans are performed at routine intervals as follows:
|
|
|
|
|
References
- ↑ Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ; et al. (2013). "Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (8): 917–23. PMID 23946171.
- ↑ Chan, A. T. C.; Gregoire, V.; Lefebvre, J.- L.; Licitra, L.; Hui, E. P.; Leung, S. F.; Felip, E. (2012). "Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Annals of Oncology. 23 (suppl 7): vii83–vii85. doi:10.1093/annonc/mds266. ISSN 0923-7534.